MX2015002378A - Composicion ansiolitica, formulacion y metodo de uso. - Google Patents

Composicion ansiolitica, formulacion y metodo de uso.

Info

Publication number
MX2015002378A
MX2015002378A MX2015002378A MX2015002378A MX2015002378A MX 2015002378 A MX2015002378 A MX 2015002378A MX 2015002378 A MX2015002378 A MX 2015002378A MX 2015002378 A MX2015002378 A MX 2015002378A MX 2015002378 A MX2015002378 A MX 2015002378A
Authority
MX
Mexico
Prior art keywords
receptor antagonist
nmda receptor
composition
subject
ansiolitic
Prior art date
Application number
MX2015002378A
Other languages
English (en)
Spanish (es)
Inventor
Stuart L Weg
Original Assignee
Stuart L Weg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stuart L Weg filed Critical Stuart L Weg
Publication of MX2015002378A publication Critical patent/MX2015002378A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2015002378A 2012-08-23 2013-08-23 Composicion ansiolitica, formulacion y metodo de uso. MX2015002378A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261692380P 2012-08-23 2012-08-23
PCT/US2013/056424 WO2014031975A1 (en) 2012-08-23 2013-08-23 Anxiolytic composition, formulation and method of use

Publications (1)

Publication Number Publication Date
MX2015002378A true MX2015002378A (es) 2015-09-25

Family

ID=50148531

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015002378A MX2015002378A (es) 2012-08-23 2013-08-23 Composicion ansiolitica, formulacion y metodo de uso.

Country Status (11)

Country Link
US (4) US20140057988A1 (enExample)
EP (2) EP3878442A1 (enExample)
JP (2) JP6722453B2 (enExample)
KR (1) KR20150096370A (enExample)
CN (1) CN104902883A (enExample)
AU (1) AU2013305580A1 (enExample)
BR (1) BR112015003796A2 (enExample)
IL (1) IL237340A0 (enExample)
MX (1) MX2015002378A (enExample)
SG (1) SG11201501292UA (enExample)
WO (1) WO2014031975A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20200404A1 (es) 2013-03-15 2020-02-26 Janssen Pharmaceutica Nv Composicion farmaceutica de clorhidrato de s-ketamina
EP3498268A1 (en) * 2013-03-15 2019-06-19 Janssen Pharmaceutica NV Pharmaceutical composition of s-ketamine hydrochloride
EP2983787B1 (en) 2013-04-12 2019-10-02 Icahn School of Medicine at Mount Sinai Method for treating post-traumatic stress disorder
WO2015037248A1 (en) 2013-09-13 2015-03-19 National University Corporation Chiba University Application of r-ketamine and salt thereof as pharmaceuticals
CA2957926A1 (en) 2014-08-13 2016-02-18 Janssen Pharmaceutica Nv Method for the treatment of depression
JP6757537B2 (ja) * 2014-08-29 2020-09-23 公益財団法人ヒューマンサイエンス振興財団 神経疾患モデル動物の製造方法及び神経疾患モデル動物
KR20170054470A (ko) 2014-09-15 2017-05-17 얀센 파마슈티카 엔.브이. VAL66MET (SNP rs6265) 유전자형 특이적 투여 계획 및 우울증 치료 방법
EP3085366A1 (en) * 2015-04-22 2016-10-26 Institut du Cerveau et de la Moelle Epiniere-ICM Nmda antagonists for the treatment of mental disorders with occurrence of aggressive and/or impulsive behavior
US20160332962A1 (en) 2015-05-13 2016-11-17 Janssen Pharmaceutica Nv (s)-csa salt of s-ketamine, (r)-csa salt of s-ketamine and processes for the preparation of s-ketamine
SI3297619T1 (sl) * 2015-05-22 2023-02-28 Vistagen Therapeutics, Inc., Terapevtske uporabe L-4-klorokinurenina
AU2016288188B2 (en) 2015-06-27 2021-08-05 Shenox Pharmaceuticals, Llc Ketamine transdermal delivery system
CN105249531A (zh) * 2015-08-06 2016-01-20 云南中烟工业有限责任公司 一种金丝楠木提取物的制备方法及其应用
SG10202012842SA (en) * 2015-09-08 2021-01-28 Childrens Hospital Philadelphia Nonselective metabotropic glutamate receptor activators for treatment of attention deficit disorder and 22q syndrome
WO2017087691A1 (en) * 2015-11-17 2017-05-26 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders and their associated symptoms
US20200009081A1 (en) 2017-09-13 2020-01-09 Janssen Pharmaceutica N.V. Delivery Of Esketamine For The Treatment Of Depression
US11491120B2 (en) 2017-11-09 2022-11-08 The Trustees Of Columbia University In The City Of New York Pharmacological prophylactics against stress-induced affective disorders in females
US11622948B2 (en) 2017-11-09 2023-04-11 The Trustees Of Columbia University In The City Of New York Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
FR3075038B1 (fr) * 2017-12-15 2020-03-06 Melchior Material And Life Science France Utilisation de la fluoroethylnormemantine pour la prevention de l'apparition et le traitement de l'anxiete
IL275482B1 (en) 2017-12-22 2025-03-01 Janssen Pharmaceuticals Inc Esketamine for the treatment of depression
EP3505157B1 (en) 2017-12-29 2021-12-08 Celon Pharma S.A. Dry powder ketamine composition for pulmonary administration in treatment-resistant depression
EP3753557B1 (en) 2018-02-15 2025-11-05 National University Corporation Chiba University Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases
EP3813808A4 (en) 2018-05-04 2022-01-26 Perception Neuroscience, Inc. Methods of treating substance abuse
US12090145B2 (en) * 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
BR112021016404A2 (pt) 2019-02-22 2021-10-13 Harima Chemicals, Incorporated Método de aplicação de material de brasagem sólido, método de produção de peça de trabalho revestida, aparelho de aplicação e material de brasagem sólido de perfil laminado
WO2020178653A1 (en) 2019-03-05 2020-09-10 Janssen Pharmaceuticals, Inc. Esketamine for the treatment of depression
WO2020232246A1 (en) * 2019-05-15 2020-11-19 The Trustees Of Columbia University In The City Of New York Compositions and methods against stress-induced affective disorders and their associated symptoms
ES2977185T3 (es) * 2019-05-31 2024-08-20 Afyx Dev A/S Administración intranasal de ketamina a pacientes con cefalea en racimos
CN115135317A (zh) 2020-01-22 2022-09-30 西洛斯治疗有限公司 减少nmda拮抗剂的副作用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543434A (en) * 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
US5679714A (en) * 1995-06-07 1997-10-21 Weg; Stuart L. Administration of ketamine for detoxification and treatment of tobacco addiction
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
US6391922B1 (en) * 1998-01-13 2002-05-21 Synchroneuron, Llc Treatment of posttraumatic stress disorder, obsessive-compulsive disorder and related neuropsychiatric disorders
EP1103256A1 (de) * 1999-11-26 2001-05-30 Claudius Dr. med. Böck Verwendung von Ketamin zur Behandlung von neuroendokriner Immundysfunktion und algogenem Psychosyndrom
JP2009530385A (ja) * 2006-03-22 2009-08-27 マウント シナイ スクール オブ メディシン うつ病の治療のためのケタミンの鼻内投与
CA2685344A1 (en) * 2007-04-26 2008-11-06 Auspex Pharmaceuticals, Inc. Deuterium labelled ketamine
US20110038807A1 (en) * 2009-08-14 2011-02-17 Demitri Papolos Compositions and methods for treating bipolar disorder

Also Published As

Publication number Publication date
JP6771512B2 (ja) 2020-10-21
US20250255834A1 (en) 2025-08-14
US20220160655A1 (en) 2022-05-26
US20180235906A1 (en) 2018-08-23
JP2016501828A (ja) 2016-01-21
EP3878442A1 (en) 2021-09-15
CN104902883A (zh) 2015-09-09
EP2887930A1 (en) 2015-07-01
KR20150096370A (ko) 2015-08-24
JP6722453B2 (ja) 2020-07-15
SG11201501292UA (en) 2015-05-28
EP2887930A4 (en) 2016-03-23
IL237340A0 (en) 2015-04-30
JP2018162302A (ja) 2018-10-18
BR112015003796A2 (pt) 2017-07-04
US20140057988A1 (en) 2014-02-27
WO2014031975A1 (en) 2014-02-27
AU2013305580A1 (en) 2015-04-09

Similar Documents

Publication Publication Date Title
MX2015002378A (es) Composicion ansiolitica, formulacion y metodo de uso.
ECSP17022931A (es) Uso de un agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamiento de la enfermedad del hígado graso no alchólico
CO6400170A2 (es) Agosnistas y antagonistas del receptor s1p5 y métodos de uso de los mismos
CO6771417A2 (es) Antagonistas del receptor de ácido lisofosfatidico y su uso en el tratamiento de fibrosis
ECSP19047259A (es) Combinación farmacéutica para el tratamiento del dolor
SV2015005115A (es) Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades
CL2013003527A1 (es) Compuestos heterociclicos antagonistas de los receptores muscarinicos y agonistas del receptor beta2 adrenergico; su composicion farmaceutica; su combinacion; un dispositivo y su uso en la prevencion y/o el tratamiento de enfermedades bronco-obstructivas o inflamatorias como asma y epoc.
UY35210A (es) Inhibidores de autotaxina
CL2013001093A1 (es) Compuestos triciclicos inhibidores de la quinasa pi3 (pi3k); composicion farmaceutica que los comprende; metodo para tratar el cancer; y su uso para el tratamiento del cancer .
CL2013001677A1 (es) Compuestos derivados de azabiciclo[3.2.1]octano; agonista del receptor x fernesoide (fxr); proceso para preparar los compuestos; compuesto intermediario; composicion farmaceutica y combinacion farmaceutica que comporenden un compuesto; y uso de los compuestos en la preparacion de medicamentos para el tratamiento de dislipidemia.
MX377410B (es) Antagonistas de receptores de integrina y sus metodos de uso.
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
GT201400196A (es) Compuestos de heterociclilo
CO6410279A2 (es) Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, forma farmacéutica de la misma, procedimiento para su preparación y usos de la misma para el control glucémico mejorado en un paciente.
GT201000182A (es) Regimen de dosificacion asociado con ésteres de paliperidona inyectables de acción prolongada
CO7400870A2 (es) Compuestos derivadios de quinuclidina con actividad antagonista de los receptores muscarínicos y actividad agonista del receptor beta2 adrenérgico
MX361778B (es) Composiciones farmaceuticas y metodos de tratamiento.
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
SV2017005530A (es) Combinaciones que contienen 2,3- dihidroimidazo[1,2-c]quinazolina sustituida
CL2017003066A1 (es) Composiciones de carbonato de calcio amorfo para administración mediante inhalación, sublingual o bucal
MX2017000627A (es) Metodos para tratar pacientes con hipercolesterolemia familiar heterocigota (hfhe).
MX2013007622A (es) Combinacion de un agonista opioide y un antagonista opioide en el tratamiento de la enfermedad de parkinson.
GT201500094A (es) Derivados de pirrolotriazinona como inhibidores de pi3k
CO6491060A2 (es) Compuestos y composiciones para el tratamiento de enfermedades parasitarias
MX2018003893A (es) Moduladores del receptor p2x3 y p2x2/3 de diaminopirimidina para usarse en el tratamiento de la tos.